Argenx stock trades near 12-month high as analysts see further upside

Published on 09/11/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock closed at USD 984.04 on Nasdaq on September 9, 2026, leaving the shares close to a reported 12-month high around USD 1,072.75. Analyst-based AI models point to an upside target of USD 1,040.45 with a high scenario of USD 1,311.41.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx SE stock (ISIN NL0010832176) finished at USD 984.04 on the Nasdaq on September 9, 2026, down 1.82 percent from a prior close of USD 1,002.31 but still trading near the upper end of its recent 12-month range. As an analyst-based AI comparison highlighted on September 10, 2026, the shares carry an upside target of USD 1,040.45 and a high scenario of USD 1,311.41, underscoring that Argenx remains priced for growth in the biotech segment.

Analyst AI targets frame upside

Based on an AI-driven comparison published by Danelfin on September 10, 2026, Argenx SE was assigned an AI price target of USD 1,040.45, with a high forecast of USD 1,311.41 and a low forecast of USD 670.13, implying potential upside of about 3.8 percent from a reference price of USD 1,002.35 at the time of the analysis.Ad-hoc-news The same comparison placed that USD 1,002.35 price in the upper part of Argenx's recent trading range, with the moderate gap to USD 1,040.45 contrasting with the much larger distance to the USD 1,311.41 high case, suggesting that the market has already priced in a significant portion of expected growth.

The AI-based analysis also noted that Argenx shares were trading near a reported 12-month high around USD 1,072.75 as of early September 2026, reinforcing the notion that the stock is close to levels many investors view as a key technical reference point.Ad-hoc-news For investors, this setup means that short-term moves increasingly depend on whether upcoming clinical and commercial milestones can justify a move beyond the 12-month high or whether the shares consolidate around current levels.

Recent trading keeps Argenx near the top of its range

Argenx SE (Nasdaq: ARGX) closed at USD 984.04 on the Nasdaq on September 9, 2026, compared with a prior close of USD 1,002.31, marking a decline of USD 18.27 or 1.82 percent.Ad-hoc-news Despite this pullback, intraday trading kept the price within a band that the AI comparison referenced with a value of USD 1,007.07 as of September 9, 2026, illustrating that the stock continues to oscillate close to the upper end of its 12-month range rather than retreating toward the midpoint.

In that context, Argenx stock thus stood at USD 1,007.07 on the Nasdaq as of September 9, 2026, in United States dollars, with that close near the upper end of its recent range and not far below the reported 12-month high around USD 1,072.75.Ad-hoc-news The roughly USD 65.68 spread between the September 9, 2026 close at USD 1,007.07 and the 12-month high around USD 1,072.75 indicates that the stock is within a single-digit percentage distance of that peak, a level that often acts as resistance unless new catalysts emerge.

Market data around the same time showed that the broader equity backdrop was weak, with the Dow Jones Industrial Average falling about 0.8 percent to 52,380.66 on September 10, 2026, highlighting a risk-off tone that weighed particularly on growth and biotech names.Ad-hoc-news Against this backdrop, Argenx's 1.82 percent decline on September 9, 2026 left the stock lagging slightly behind the Nasdaq Composite, which also slipped but by a smaller percentage, underscoring the sensitivity of high-valuation biotech shares to changes in risk appetite.

Stock stays close to key resistance levels

For investors watching Argenx stock, the combination of an AI-derived target of USD 1,040.45 and a high scenario of USD 1,311.41 with a last observed price around USD 1,002.35 provides a quantified framework for potential upside and downside.Ad-hoc-news The approximately 3.8 percent gap between USD 1,002.35 and USD 1,040.45 is modest compared with the more than USD 300 distance to USD 1,311.41, indicating that the base case already assumes incremental gains while the bullish case would require a strong sequence of clinical and commercial achievements.

At the same time, the low forecast of USD 670.13 in the same AI comparison illustrates the degree of downside in a scenario where expectations are not met, with that level standing more than USD 300 below the USD 1,002.35 reference price.Ad-hoc-news This spread between the high and low scenarios underscores that, while the stock currently trades close to its 12-month high, it remains exposed to binary outcomes typical for companies with pivotal clinical programs.

Argenx stock price snapshot

Argenx SE stock closed at USD 984.04 on the Nasdaq on September 9, 2026, in US dollars, representing a 1.82 percent decline from the prior day and leaving the shares within a narrow band of recent prices near the reported 12-month high around USD 1,072.75. The trading venue for the reference price is the Nasdaq, where Argenx is listed under the ticker ARGX, and the closing level positions the stock close to technical resistance that many market participants monitor.